Thinq Pharma-cro Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA.
One of their notable products is SUCRALFATE USP, with a corresponding US DMF Number 40145.
Remarkably, this DMF maintains an Active status since its submission on July 04, 2024, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of August 05, 2024, and payment made on July 03, 2024, indicating their dedication to facilitating drug approvals, Categorized as Type II